Research on the clinical value evaluation of multiple myeloma therapeutic drugs from the perspective of venture capitalYANG Ting-ting, KE Chao-jing, WU Xia, ZHOU Bin1321-1325
Research hotspots of natural products base on co-word analysisNI Bing-wei, ZHAO Hong-ping, GU Yue-qing1326-1333
Discussion about efficacy endpoints of clinical trials of coagulation factor Ⅷ and Ⅸ for hemophilia on demandRAO Ya-lan, JI Shuang-min, XIONG Wen-xiang, YU Ai-ping, YANG Huan, GAO Chen-yan1338-1342
CMC considerations for additional strength biowaiver of oral solid generic drugsHU Yan-chen, KANG Jian-lei1343-1348
Establishment and validation of UPLC-MS/MS method for determination of an innovative antitumor drug SM-1 in plasma of Beagle dogsLIU Shu-jie, YU Min, WANG Yu, HUANG Shu-jia, DAN Mo, LI Zuo-gang, GENG Xing-chao, ZHANG He-zhan, YANG Jin-bo, LIU Li1349-1354
Application of multivariate analysis method in generic drug quality evaluationZHAO Yu, HU Chang-qin, YAO Shang-chen, YIN Li-hui, LING Xiao-mei1355-1362
Recent advances in research on targets and drugs for treatment of non-alcoholic fatty liver diseaseZHOU Zong-tao, DENG Li-ming, HU Li-jun, REN Qiang, ZHANG Lu-yong, LI Zheng1363-1374
Progress in clinical application of tyrosine kinase inhibitor osimertinib in non-small cell lung cancerZHANG Cong-hui, LIU Jian1375-1381
Epidemiological investigation of echinocandin-resistant CandidaZHANG Wei, HUANG Jing-jing, XIAO Meng, XU Ying-chun1382-1386